Using MRI to Measure Blood Flow in the Eye
Arterial Spin Labeling MRI for Assessing Blood Perfusion in the Human Eye Repeatability Study and Clinical Application
This study is testing a new MRI method to see if it can safely measure blood flow in the eyes of patients with certain optic nerve conditions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels, Brussels Capital) |
| Trial ID | NCT05724641 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of arterial spin labeling (ASL) MRI, a non-invasive imaging technique, to assess blood perfusion in the human eye. By measuring parameters such as regional blood flow and cerebral blood flow, the study aims to establish the reliability and specificity of the MRI protocol for evaluating retinal diseases. Participants will undergo MRI scans without the need for contrast agents, allowing for a safer assessment of their eye conditions. The study focuses on patients with specific optic neuropathies while ensuring they meet certain health criteria.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with TAO optic neuropathy, inflammatory optic neuropathy, or ischemic optic neuropathy who do not have cardiovascular risk factors or other eye conditions.
Not a fit: Patients with contraindications to MRI, such as those with pacemakers or severe claustrophobia, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable, non-invasive method for assessing blood flow in the eye, improving diagnosis and management of retinal diseases.
How similar studies have performed: While the use of ASL MRI is a relatively novel approach in this context, similar studies have shown promise in other areas of perfusion imaging.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Carrier of target pathologies: TAO optic neuropathy, inflammatory optic neuropathy, ischemic optic neuropathy. * no cardiovascular risk factors or other ophthalmological pathology * adhere to the study protocol after reading the patient information document * signe the informed consent form to participate in the study * do not have any contraindications to an MRI examination Exclusion criteria * Usual contraindications to MRI (Pacemaker, Metallic foreign body, Cochlear implant,…) * Severe claustrophobia
Where this trial is running
Brussels, Brussels Capital
- Cliniques Universitaires Saint Luc — Brussels, Brussels Capital, Belgium (Recruiting)
Study contacts
- Principal investigator: Idil Günes-Tatar, MD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Idil Günes-Tatar, MD
- Email: idil.gunes@saintluc.uclouvain.be
- Phone: +32.276442544
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.